FDA Approved: VYNDAMAX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approved a supplemental application for VYNDAMAX (tafamidis) submitted by Pfizer Laboratories Div Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy
• Transthyretin Amyloid Polyneuropathy
• Transthyretin Amyloidosis

Drugs mentioned

• Vyndamax (tafamidis)

Snippet

SUPPL AP for VYNDAMAX (TAFAMIDIS)